News headlines about Alimera Sciences (NASDAQ:ALIM) have been trending somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Alimera Sciences earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.9306982701349 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Several equities research analysts have commented on ALIM shares. Zacks Investment Research raised shares of Alimera Sciences from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research note on Tuesday, April 10th. HC Wainwright set a $3.00 target price on shares of Alimera Sciences and gave the company a “buy” rating in a research note on Tuesday, May 8th. Finally, ValuEngine raised shares of Alimera Sciences from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd.
NASDAQ:ALIM traded up $0.01 during trading hours on Friday, hitting $0.88. The stock had a trading volume of 139,904 shares, compared to its average volume of 131,987. Alimera Sciences has a one year low of $0.74 and a one year high of $1.65. The company has a debt-to-equity ratio of -0.62, a quick ratio of 4.64 and a current ratio of 4.81. The company has a market capitalization of $60.86 million, a PE ratio of -3.03 and a beta of 1.50.
About Alimera Sciences
Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.